Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3results about How to "Reduce fusion" patented technology

A multi-modal attention and feature fusion framework for remote sensing image fusion

PendingCN122714917ASolve the problem of computational redundancyreduce in quantity
The application provides a kind of multimodal attention and feature fusion framework for remote sensing image fusion, belongs to remote sensing information processing technical field, including five layers encoder-decoder architecture, the architecture includes hybrid attention and multiscale fusion (HAMF) module, adversarial feature fusion (AFF) module and cross-domain regularization (CDR) module.The application preprocesses the hyperspectral, multispectral image of input through the framework;Through HAMF module, feature extraction and enhancement are carried out;Through AFF module, feature alignment, information maximization and adversarial optimization are carried out;Through CDR module, domain adversarial training and regularization operation are carried out, the cross-domain generalization ability of the framework is improved, finally a composite loss function is constructed to train the whole framework end to end, and iteration is carried out until convergence, so that each evaluation index of the fusion image is obviously improved, and the fusion image with high-quality spectral information and clear spatial details is output.
Owner:TONGJI UNIV

Application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease

PendingCN122075541AImprove pathological changesreduce fusionMammal material medical ingredientsRespiratory disorderDiseaseInflammatory factors
This invention relates to the application of mitochondrial formulations in the preparation of drugs for treating chronic obstructive pulmonary disease (COPD). The mitochondrial formulations contain active mitochondria isolated from healthy donor cells, with a particle size of 400–1000 nm, possessing normal mitochondrial membrane potential and ATP generation function, and capable of being internalized by mammalian COPD lung epithelial cells. In vitro cell experiments have confirmed that this mitochondrial formulation can repair CSE-induced mitochondrial dysfunction in lung epithelial cells, inhibit mPTP opening, reduce mtDNA leakage into the cytoplasm, thereby blocking the activation of the cGAS-STING signaling pathway and reducing the release of inflammatory factors such as IL-1β and TNF-α. In vivo experiments in COPD mouse models show that tail vein injection of the mitochondrial formulation can effectively accumulate in lung tissue, significantly improving lung pathological changes such as emphysema and collagen fiber deposition in model mice. This invention provides a novel strategy for COPD treatment based on repairing mitochondrial function and intervening in inflammatory signaling pathways.
Owner:SHANGHAI MICROZHENZI BIOTECHNOLOGY CO LTD